InsuQuick Cartridge (3ml each) contains Insulin Aspart at a concentration of 100 units per milliliter, a rapid-acting insulin analog indicated for the management of hyperglycemia in patients with diabetes mellitus. Insulin Aspart facilitates glucose uptake into peripheral tissues and inhibits hepatic glucose production, thereby aiding in the control of postprandial blood glucose levels. The rapid onset of action, typically within 10 to 20 minutes after subcutaneous administration, allows for administration shortly before or immediately after meals, providing improved glycemic control compared to regular human insulin. Each cartridge contains 3ml of sterile insulin solution designed for use with compatible insulin delivery devices. InsuQuick Cartridge is intended for subcutaneous injection and should not be administered intravenously or intramuscularly. Dosage and administration must be individualized based on patient-specific factors including blood glucose monitoring, meal patterns, and insulin sensitivity. Patients should be educated on proper injection techniques, storage conditions, and recognition of hypoglycemia symptoms. InsuQuick Cartridge is contraindicated in patients with hypersensitivity to Insulin Aspart or any excipients. Caution is advised in patients with renal or hepatic impairment. This product is an essential component in intensive insulin therapy regimens aimed at achieving optimal glycemic control and reducing the risk of diabetes-related complications.